Συγγραφείς:
Karampitsakos, T.
Papaioannou, O.
Dimeas, I.
Tsiri, P.
Sotiropoulou, V.
Tomos, I.
Papanikolaou, I.C.
Katsaras, M.
Kirgou, P.
Daniil, Z.
Gourgoulianis, K.I.
Sampsonas, F.
Manali, E.
Papiris, S.
Bouros, D.
Tzouvelekis, A.
Λέξεις-κλειδιά:
antifibrotic agent; B cell activating factor receptor; carbon monoxide; messenger RNA; RNA vaccine; tozinameran, bronchiectasis; coronavirus disease 2019; disease activity; down regulation; fibrosing alveolitis; forced expiratory volume; forced vital capacity; human; immune response; immunocompromised patient; immunogenicity; immunosuppressive treatment; Kolmogorov Smirnov test; Letter; lung artery pressure; mortality; obesity; practice guideline; prevalence; public health; risk factor; Severe acute respiratory syndrome coronavirus 2; vaccination
